Mitochon Pharmaceuticals


Mitochon Pharmaceuticals is a clinical-stage biotech company focused on developing drugs that target mitochondrial dysfunction to treat serious neurodegenerative and neuromuscular diseases. Their mission is to create meaningful therapies that modulate mitochondrial physiology to slow disease progression and improve patient outcomes. Mitochon aims to open the door for a broad range of disease-modifying therapies by correcting mitochondrial dysfunctions linked to various diseases.

Mitochon Pharmaceuticals Logo

Mitochon Pharmaceuticals

970 Cross Lane, Blue Bell, PA 19422


Patents

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

2023-08-08 • US-11717497-B2

View Details

DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases

2022-08-09 • US-11406642-B2

View Details

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

2020-12-15 • US-10864173-B2

View Details

DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases

2020-02-04 • US-10548900-B2

View Details

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of Neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

2019-03-05 • US-10220006-B2

View Details

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

2018-05-22 • US-9974755-B2

View Details

What We Do

A mitochondrial uncoupling prodrug aimed at treating neurodegenerative diseases such as ALS, Huntington's Disease, and Parkinson's Disease.

A slow-release mitochondrial uncoupling prodrug designed for conditions like Traumatic Brain Injury and Multiple Sclerosis.


Digital Health Technologies

Diagnostics


Key People

Founder & CEO

Founder & Chief Scientific Officer

Acting Chief Medical Officer


News & Updates

Research published on November 18, 2024, demonstrating the efficacy of micro-doses of DNP in ALS models.

Announcement on January 9, 2024, regarding the initiation of a biomarker study for neurodegenerative diseases.

An article discussing the potential of Mitochon’s drugs in treating traumatic brain injuries, published on May 6, 2024.

An article published on April 4, 2023, discussing Mitochon’s approach to neurodegeneration and aging.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.